CliffBio
small molecule

ADAPALENE

ADAPALENE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameADAPALENE
Active ingredientADAPALENE
Strength0.3%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalJune 2020
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.